Colorectal adenocarcinoma patients with M1a diseases gain more clinical benefits from palliative primary tumor resection than those with M1b diseases: A propensity score matching analysis

Table 3 Survival time for metastatic colorectal adenocarcinoma patients with or without palliative primary tumor resection

	Median survival time (95%CI)	1-yr survival rate (%)	3-yr survival rate (%)
M1a (total)
No surgery	14 (13.275-14.725)	54.4	13.9
Surgery	23 (21.977-24.023)	70.4	32.6
M1a (liver metastasis)
No surgery	14 (13.320-14.780)	53.8	13.4
Surgery	22 (20.955-23.045)	69.2	29.8
M1a (lung metastasis)
No surgery	18 (15.692-20.308)	62.2	18.6
Surgery	33 (28.014-37.986)	77.5	45.4
M1b
No surgery	10 (9.401-10.599)	42.2	8.6
Surgery	17 (16.209-17.791)	60.0	20.4